Interaction of oxycodone and voriconazole - A case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects

European Journal of Clinical Pharmacology

Volumn 67, Issue 8, 2011, Pages 863-864

  Hagelberg, Nora M ^a   Nieminen, Tuija H ^a   Saari, Teijo I ^a   Neuvonen, Mikko ^b   Neuvonen, Pertti J ^b   Laine, Kari ^c   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; NARCOTIC ANALGESIC AGENT; OXYCODONE; VORICONAZOLE;

ADVERSE OUTCOME; ANALGESIA; BREATHING DISORDER; BURKITT LYMPHOMA; CANCER PAIN; CLINICAL EFFECTIVENESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAPEFRUIT JUICE; HUMAN; LETTER; MYCOSIS; PAIN; PRIORITY JOURNAL; VOMITING;

ANALGESICS, OPIOID; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BURKITT LYMPHOMA; CHRONIC PAIN; FEMALE; HUMANS; MALE; OXYCODONE; PYRIMIDINES; TRIAZOLES;

EID: 79960940740     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-010-0969-0     Document Type: Letter

References (9)

1. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2009) Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65:263-271
2. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT (2010) Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and CYP3A pathways but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 70:78-87
3. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2010) Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 66:977-985
4. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2010) Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin Pharmacol Toxicol 107:782-788
5. Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 66:387-397
6. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160:907-918
7. Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S (2010) Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol. doi:10.1007/s00228-010- 0893-3
8. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 160:919-930
9. Watanabe M, Homma M, Momo K, Okoshi Y, Wada T, Hara A, Chiba S, Kohda Y (2011) Effects of voriconazole co-administration on oxycodone-induced adverse effects - a case in the retrospective survey. Eur J Clin Pharmacol (in press)